SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Johnny Cash — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJohnny Cash
Date of birth1932-02-26
IdentifiersMRN HR-ML004-SYN-TD; SSN (made up) 000-04-8125
Document date2003-05-29
AuthorGideon Hale, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month diabetes, blood pressure, and eye pressure review. [S]

History of Present Illness

Mr. Cash returns for his three-month review, nine weeks after sitagliptin and midodrine 2.5 mg were started and five weeks after his annual wellness visit. His fasting home readings now run 120 to 150 mg/dL, with none below 70. He is less lightheaded than before midodrine, but he still feels faint for a minute or two after getting up in the morning and after lunch, and he has had no falls. He takes the last midodrine by mid-afternoon and has no scalp tingling or trouble passing urine. He has started physical therapy for gait and balance, and the low-vision home visit is booked. He uses both eye drops every day without stinging. No eye pressure check was done between visits. He is writing and recording at home. [S]

ElementDetail
Interval changeLess lightheaded; still briefly faint after rising and after lunch; no falls
Home glucoseFasting 120 to 150 mg/dL; none below 70
Midodrine toleranceLast dose by mid-afternoon; no scalp tingling or urinary retention
RehabilitationPhysical therapy started; low-vision home visit booked
Eye dropsLatanoprost and dorzolamide daily; no stinging

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight down 0.7 kg since the wellness visit; no fever
EyesPositiveTunnel vision and poor vision in dim light, unchanged; no eye pain or redness
CardiovascularPositiveBriefly faint after rising and after lunch; no fainting or chest pain
GenitourinaryNegativeNo difficulty passing urine
MusculoskeletalNegativeNo muscle aches on atorvastatin
PsychiatricNegativeMood good; PHQ-2 score 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 500 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2001-05-06 to 2003-02-27completedS
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2003-02-27activeS
Sitagliptin 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2003-03-27activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2003-02-27activeS
Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtimeOne drop in each eye at bedtimeOphthalmic route2000-09-11activeS
Dorzolamide 2% ophthalmic solution, one drop in each eye twice dailyOne drop in each eye twice dailyOphthalmic route2003-02-27activeS
Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PMOne tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bedOral route2003-03-27 to 2003-05-29completedS
Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PMOne tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bedOral route2003-05-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2003-05-29Body height188cmS
2003-05-29Body weight93.5kgS
2003-05-29Body mass index (BMI) [Ratio]26.5kg/m2S
2003-05-29Systolic blood pressure136mm[Hg]S
2003-05-29Diastolic blood pressure76mm[Hg]S
2003-05-29Heart rate74/minS
2003-05-29Respiratory rate16/minS
2003-05-29Body temperature36.7CelS
2003-05-29Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2003-05-29Hemoglobin A1c/Hemoglobin.total in Blood7.7%<=5.6%HighS
2003-05-29Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation74mg/dL<=99 mg/dLNormalS
2003-05-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-56 U/LNormalS
2003-05-29Right eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2003-05-29Left eye Intraocular pressure16mm[Hg]10-21 mmHgNormalS
2003-05-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2003-05-29; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and well; walks with a cane
EyesConjunctivae quiet; eye pressure 15 mmHg right and 16 mmHg left by applanation at the eye clinic today
CardiovascularRegular rhythm; blood pressure 146/82 mmHg lying, 136/76 mmHg seated, and 114/70 mmHg after three minutes standing, with lightheadedness
FeetSkin intact; no ulcers or calluses; sensory loss to the ankles unchanged; protective shoes

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intakeactiveconfirmed E11.43S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy.
Neurogenic orthostatic hypotension from diabetic autonomic neuropathyactiveconfirmed I95.1S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome.
Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feetactiveconfirmed E11.42S — Synthetic finding linked to his description of numb lower extremities.
Primary open-angle glaucoma, both eyes, severe stageactiveconfirmed H40.1133S — Synthetic modern diagnosis; the type and stage are not documented historically.
Mild nonproliferative diabetic retinopathy without macular edema, both eyesactiveconfirmed E11.3293S — Synthetic finding from the dilated eye examination.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
History of recurrent pneumoniaactiveconfirmed Z87.01S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHbA1cEvery 3 months until at goal or after a therapy change; every 6 months when stableCompleted today7.7%, down from 8.6%; not yet at goal, so repeat in three months
LaboratoryLipid panel after starting a statin4 to 12 weeks after a statin starts or changesCompleted todayLDL 74 mg/dL, a 42 percent fall. Drawn at 13 weeks, one week after the window closed, because the panel was scheduled for this review instead of inside the window: a minor deviation from the protocol. No harm resulted; there was no dose decision that an earlier result would have changed
LaboratoryALTOnce before a statin; afterward only for symptomsCompleted today27 U/L, normal; no further routine checks
LaboratoryALT, AST, and platelets for FIB-4At diagnosis and yearlyDeferredFIB-4 could not be calculated at intake because no platelet count was drawn with the hemoglobin, a deviation from the protocol. ALT and AST were normal at intake and ALT is normal today, so missed liver scarring is unlikely; AST and a platelet count are added to the annual tests
LaboratoryLipoprotein(a)Once in adulthoodDeferredNot yet measured, a deviation from the protocol. It would not change treatment now, since he already takes a high-intensity statin; added to the annual lipid panel
ExaminationBlood pressure, weight, and BMIEvery visitCompleted todaySeated 136/76 mmHg; weight 93.5 kg
ExaminationLying, seated, and standing blood pressureEvery visitCompleted todayLying 146/82, standing 114/70 mmHg; no supine hypertension
ExaminationFoot examination (inspection, pulses, monofilament)Every visit with loss of protective sensationCompleted todayNo ulcer; sensory loss unchanged
ExaminationTonometry (eye pressure)Every glaucoma visit; 4 to 6 weeks after adding a dropCompleted today15 mmHg right and 16 mmHg left, at target. This is the first check since dorzolamide was added three months ago; the check at four to six weeks was missed (see the four-week note). The pressure has reached target, and the six-month OCT and fields will show whether the delay cost any nerve tissue
ExaminationDrop adherence, ocular surface, and systemic effects of glaucoma dropsEvery visitCompleted todayBoth drops used daily; no stinging; no effect on pulse or blood pressure
ImagingOCT of the optic nerve and nerve fiber layer, and visual fieldsEvery 6 months in severe glaucomaDueAt the six-month review with the eye clinic
SurveyHypoglycemia review and home glucose logEvery visitCompleted todayNo readings below 70 mg/dL
SurveyDepression screen (PHQ-2)At least yearlyCompleted todayScore 0
SurveyTobacco useEvery visitCompleted todayNo tobacco use
Medication safetyMidodrine safety: lying pressure, timing, and urinary retentionEvery visit on midodrineCompleted todayLying 146/82 mmHg; last dose by mid-afternoon; no retention
Medication safetyVaccination reviewYearly, and as doses fall dueCompleted todayRecombinant zoster dose 1 given today; RSV, COVID-19, and tetanus remain due from the wellness visit
ReferralPhysical therapy and low-vision rehabilitationAfter a fall-risk findingCompleted todayPhysical therapy under way; low-vision home visit booked
Self-managementDiet, orthostatic measures, and foot self-careEvery visitCompleted todaySmaller lunches added; other measures continue

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 1 [S]

Guideline basis: Standards of Care in Diabetes—2025 (2025); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026)

Follow-up: Six-month diabetes review with HbA1c, a basic metabolic panel, urine albumin-creatinine ratio, eye pressure, OCT, and visual fields. Next scheduled visit 2003-08-14: six-month diabetes review with glaucoma imaging. [S]